Immuneering Corporation (NASDAQ:IMRX) Director Purchases $89,471.85 in Stock

Immuneering Corporation (NASDAQ:IMRX) Director Thomas J. Schall bought 40,485 shares of the firm’s stock in a transaction that occurred on Tuesday, June 17th. The stock was acquired at an average cost of $2.21 per share, with a total value of $89,471.85. Following the transaction, the director now owns 43,385 shares of the company’s stock, valued at $95,880.85. This represents a 1,396.03% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Immuneering Price Performance

Shares of IMRX stock opened at $2.56 on Friday. The stock has a market cap of $92.13 million, a P/E ratio of -1.31 and a beta of 0.01. The company has a fifty day moving average price of $1.62 and a two-hundred day moving average price of $1.75. Immuneering Corporation has a one year low of $1.00 and a one year high of $3.83.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). As a group, equities research analysts anticipate that Immuneering Corporation will post -1.86 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on IMRX. Chardan Capital reaffirmed a “buy” rating and issued a $13.00 target price on shares of Immuneering in a research report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $9.00 target price on shares of Immuneering in a research report on Wednesday. Mizuho raised their target price on shares of Immuneering from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Oppenheimer cut their price target on shares of Immuneering from $25.00 to $21.00 and set an “outperform” rating for the company in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Immuneering presently has a consensus rating of “Moderate Buy” and an average target price of $13.25.

Institutional Trading of Immuneering

Hedge funds have recently modified their holdings of the stock. Tang Capital Management LLC acquired a new stake in shares of Immuneering during the 4th quarter worth about $27,000. Jane Street Group LLC acquired a new stake in shares of Immuneering during the 1st quarter worth about $32,000. Marshall Wace LLP acquired a new stake in shares of Immuneering during the 4th quarter worth about $47,000. First Manhattan CO. LLC. acquired a new stake in shares of Immuneering during the 4th quarter worth about $71,000. Finally, XTX Topco Ltd lifted its stake in shares of Immuneering by 177.2% during the 4th quarter. XTX Topco Ltd now owns 32,650 shares of the company’s stock worth $72,000 after buying an additional 20,871 shares during the last quarter. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.